Population-based research on the epidemiology of critical limb ischemia (CLI) in Western Europe remains almost non-existent.  To date, the number of people suffering from CLI has generally been estimated based on fewer than 5 papers published on specific European populations.

CLI Volume II contains a comprehensive analysis of the 2007 prevalence of diabetes, peripheral arterial disease (PAD) and critical limb ischemia in each of the 15 major Western European markets.  The prevalence of PAD and CLI are projected for the 2000-2020 periods.  Based on the 2007-2020 projections the market opportunities for endovascular and pharmaceutical therapies to treat critical limb ischemia are assessed.

Prevalence is defined as the number of new and old cases of critical limb ischemia.

Peer-reviewed research on the incidence and prevalence of diabetes, peripheral arterial disease and critical limb ischemia is reviewed, analyzed and assessed for each country. The 15 countries include: Germany, Italy, Spain, the U.K., France, Greece, the Netherlands, Austria, Switzerland, Belgium, Portugal, Sweden, Finland, Denmark and Norway.

CLI prevalence is estimated based on The Diabetes Method, which was previously validated in CLI Volume I. The Diabetes Method begins with segmenting the population of each country by age and glucose status, calculating the prevalence of peripheral arterial disease in each glucose category and finally the prevalence of critical ischemia by PAD and glucose status.

Market implications for the total Western European region are assessed for endovascular devices (stents, angioplasty atherectomy and chronic total occlusions), pharmaceuticals for risk factor modification, thrombolytics, mechanical thrombectomy devices and adjunct therapies in revascularized patients.

The number of Western European patients, as well as the number of limbs requiring endovascular revascularization, surgical bypass and specialized chronic total occlusion therapies is projected for the 2007-2020 periods. Additional market projections include the number of patients requiring risk factor modification therapies such as antihypertensives, antilipids and antiplatelets.

This report is the second of a series to be published on CLI. The first report focused on CLI epidemiology in the United States; the third will focus on new interventional and pharmaceutical therapies to treat CLI. Subsequent studies will examine the prevalence of PAD and CLI in other leading markets including Russia and Eastern Europe, the Far East, China and Latin America.

Price: $3,300

To purchase call us at 404 816-0746 or

Contact witherspoon@thesagegroup.us